Organization · Venture Capital
Convergence Partners
Convergence Partners AG is a Swiss venture capital firm focused on investing in B2B HealthTech startups across Europe. Established in 2018, it targets companies addressing significant unmet needs in the healthcare sector with strong international growth potential.
Overview
What Convergence Partners does
What Convergence Partners is
Convergence Partners AG is a Swiss venture capital firm focused on investing in B2B HealthTech startups across Europe. Established in 2018, it targets companies addressing significant unmet needs in the healthcare sector with strong international growth potential.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2018
- Approximate age
- About 8 years
- Structured capabilities
- Funder
- Last reviewed
- April 24, 2026
Official channels
Find Convergence Partners elsewhere
Open the official website or a supported primary organization account.
Capability profile
Convergence Partners as a funder
Investment thesis
Convergence Partners invests in high-impact healthcare companies, focusing on mental health, women's health, and human flourishing. They target B2B HealthTech firms with commercialized technologies and strong international growth potential.
Focus narrative
The firm primarily invests in the healthcare sector, emphasizing areas such as mental and brain health, women's health, and human flourishing and longevity. Convergence Partners typically invests up to EUR 5 million initially, with additional capital reserved for follow-on investments, targeting scalable, IP-driven business models with strong international growth potential.
Value beyond capital
Convergence Partners adds value by supporting the internationalization of portfolio companies into key markets such as Germany, China, the US, and India, leveraging local landing and scale-up partners to enhance growth opportunities.
Terms and economics
- Typical check
- $5,000,000
Focus and fit
- Stages
- Seed · Series A · Series A+
- Regions
- Europe · Global
Availability
- Currently deploying
- Yes
Portfolio and track record
Portfolio context
Notable portfolio company includes b-rayZ AG, a Zurich-based spinout from University Hospital Zurich, which has developed an AI platform for early breast cancer detection. Convergence Partners co-led an oversubscribed CHF 4M Series A round for b-rayZ.
Common questions
What to know about Convergence Partners
Upseed classifies Convergence Partners under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 24, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.